HOME >> MEDICINE >> NEWS
New drug shows promise for saving lives from heart failure

ATLANTA, Nov. 10 -- A new drug for heart failure saves lives and reduces symptoms, according to a study presented today at the American Heart Association Scientific Sessions.

The new drug, called omapatrilat, is a member of a new class of compounds called vasopeptidase inhibitors.

The results of this study, combined with others, suggest that the use of omapatrilat may reduce deaths and hospitalizations from congestive heart failure by as much as 30 percent, says Jean-Lucien Rouleau, M.D., director of cardiology, Mount Sinai Hospital Association at the University Health Network of Toronto, Canada. "It's a potential breakthrough in the treatment of congestive heart failure."

Congestive heart failure is a condition in which the heart can't pump enough blood to meet the needs of other organs in the body. It occurs in hearts that are damaged or overworked after a heart attack, high blood pressure, heart valve disease, congenital defects or infection of the heart or its valves. Drugs used to treat heart failure include digitalis, which increases the heart's pumping action; diuretics, which help eliminate the buildup of fluid in the body's tissues; and vasodilators, which expand blood vessels, allowing blood to flow more easily and making the heart's work easier and more efficient.

Among the vasodilators is a class of drugs know as angiotensin converting enzyme (ACE) inhibitors, which interfere with the body's production of angiotensin, a chemical that causes arteries to constrict.

The problem with ACE inhibitors, according to Rouleau, is that they do not work on all substances in the body that promote abnormal constriction of arteries, which is characteristic of heart failure.

The new drug works in two ways. Like conventional ACE inhibitors, it blocks the action of angiotensin, inhibiting the constrictive action of this substance. But omapatrilat also neutralizes a substance called neutral endopeptidase, resulting in blood vessels rel
'"/>

Contact: Carole Bullock
caroleb@heart.org
214-706-1279
American Heart Association
9-Nov-1999


Page: 1 2 3

Related medicine news :

1. Study shows promise in identifying kidney failure
2. Study shows patch therapy may be as effective as oral medications
3. Study shows soy is well accepted in school lunches
4. Chronic pain treatments more effective when taken together, new study shows
5. UW study shows blacks and Latinos are more satisfied with physicians of the same race
6. Vaccine against childhood pneumonia shows promise
7. UW research shows risk factors for relapse among health care professionals who abuse drugs
8. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
9. New technique shows promise for improved straightening of crooked nose
10. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
11. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New drug shows promise for saving lives from heart failure

(Date:10/31/2014)... October 31, 2014 At the start ... families narrowly escaping carbon monoxide poisoning in their homes. ... weeks away, one family-owned, Missouri-based heating and cooling company ... making sure families start the home heating season with ... secure. , Beginning Nov. 1, 2014, E and ...
(Date:10/31/2014)... -- Surgery for low back pain caused by spinal ... you live, a new report says. "Nearly 80 ... some point in their lives, and about 30 million ... spine problem," co-author Brook Martin, of the Dartmouth Institute ... college news release. In spinal stenosis, thickening of ...
(Date:10/31/2014)... DARIEN, IL – New research suggests that insomnia is ... crashes and other unintentional fatal injuries. The results underscore ... of the National Healthy Sleep Awareness Project. , Results ... in a dose-dependent manner with the number of insomnia ... were 2.8 times more likely to die from a ...
(Date:10/31/2014)... October 31, 2014 The Suspension Revolution ... workout program was developed by Dan Long, a suspension ... as a fitness professional and life coach. The author ... having toned muscles is not impossible , The Suspension ... suspension training. Suspension training promises efficiency when it comes ...
(Date:10/31/2014)... 31, 2014 Florida Air Academy, ... girls in grades 6-12, is taking the lead ... injuries and concussions, becoming the first high school ... (Immediate Post-Concussion Assessment and Cognitive Testing) computerized assessment ... Player' lawsuit grabs the headlines, and the Centers ...
Breaking Medicine News(10 mins):Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Florida Air Academy Tackling Concussions Head-On 2Health News:Florida Air Academy Tackling Concussions Head-On 3
(Date:10/31/2014)... Ga. , Oct. 31, 2014  Digirad Corporation ... to PDI, Inc. (Nasdaq: PDII ), a ... of Digirad,s proposal to acquire the company.  ... meaningful discussions regarding a transaction and to operate in ... its cash, or take on additional debt, on acquisitions ...
(Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
Cached News: